A
Amelie Renaud
Researcher at National Institutes of Health
Publications - 5
Citations - 2281
Amelie Renaud is an academic researcher from National Institutes of Health. The author has contributed to research in topics: PARP inhibitor & Olaparib. The author has an hindex of 4, co-authored 5 publications receiving 1761 citations.
Papers
More filters
Journal ArticleDOI
Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors
Junko Murai,Shar Yin N. Huang,Benu Brata Das,Amelie Renaud,Yiping Zhang,James H. Doroshow,Jiuping Ji,Shunichi Takeda,Yves Pommier +8 more
TL;DR: This study shows that PARP inhibitors trap the PARP1 and PARP2 enzymes at damaged DNA, providing a new mechanistic foundation for the rational application ofPARP inhibitors in cancer therapy.
Journal ArticleDOI
Stereospecific PARP Trapping by BMN 673 and Comparison with Olaparib and Rucaparib
Junko Murai,Shar-yin N. Huang,Amelie Renaud,Yiping Zhang,Jiuping Ji,Shunichi Takeda,Joel Morris,Beverly A. Teicher,James H. Doroshow,Yves Pommier +9 more
TL;DR: BMN 673 is the most potent clinical PARP inhibitor tested to date with the highest efficiency at trapping PARP–DNA complexes and is also approximately 100-fold more cytotoxic than olaparib and rucaparIB in combination with the DNA alkylating agents methyl methane sulfonate and temozolomide.
Journal ArticleDOI
Synthesis and Biological Evaluation of Indenoisoquinolines That Inhibit Both Tyrosyl-DNA Phosphodiesterase I (Tdp1) and Topoisomerase I (Top1)
Martin Conda-Sheridan,P. V. Narasimha Reddy,Andrew Morrell,Brooklyn T. Cobb,Christophe Marchand,Keli Agama,Adel Chergui,Amelie Renaud,Andrew G. Stephen,Lakshman Bindu,Yves Pommier,Mark Cushman +11 more
TL;DR: The design, synthesis, and evaluation of new indenoisoquinolines that are dual inhibitors of both Tdp1 and Top1 are documents, which places the more active compounds among the most potent known inhibitors of this target.
Journal ArticleDOI
5-Arylidenethioxothiazolidinones as Inhibitors of Tyrosyl-DNA Phosphodiesterase i
Venkata Ramana Sirivolu,Sanjeev Kumar V. Vernekar,Christophe Marchand,Alena Naumova,Adel Chergui,Amelie Renaud,Andrew G. Stephen,Feng Chen,Yuk Y. Sham,Yves Pommier,Zhengqiang Wang +10 more
TL;DR: Through structure-activity relationship (SAR) studies, it is demonstrated that arylidene thioxothiazolidinones inhibit Tdp1 and compound 50 is identified as a submicromolar inhibitor of TDP1 (IC₅₀ = 0.87 μM).
Proceedings ArticleDOI
Abstract A257: Stereospecific trapping of PARP-DNA complexes by BMN 673 and comparison with olaparib and rucaparib.
Junko Murai,Shar-yin N. Huang,Amelie Renaud,Yiping Zhang,Jiuping Ji,Shunichi Takeda,Joel Morris,Beverly A. Teicher,James H. Doroshow,Yves Pommier +9 more
TL;DR: It is demonstrated that BMN 673 is the most potent clinical PARP inhibitor to date with the highest efficiency at trapping PARP-DNA complexes and more cytotoxic as a single agent than olaparib.